Abstract:Xeroderma pigmentosum (XP), is a rare, autosomal recessive disease with sun sensitivity and multiple neoplasms in association with reduced DNA repair. As a reflection of the clinical consequences of deficient DNA repair, XP serves as a model for determining the effects of proficient DNA repair. To estimate the risk of developing neoplasms in XP, we abstracted reports of 726 XP patients (from 41 countries) published from 1874 to 1982. Despite limitations of a literature survey, the XP patients under age 20 years had an estimated 2000-fold increase in frequency of basal cell and squamous cell carcinoma of the skin, of cutaneous melanoma, of cancer of the anterior eye, and of cancer of the anterior tongue, in comparison to the general population. These sites are all potentially exposed to u.v. radiation, a strong carcinogen which produces DNA damage that is poorly repaired by XP cells. XP patients under age 20 years also had an estimated 12-fold increase in occurrence of neoplasms in sites not exposed to u.v. radiation. Among the XP patients under age 40 years with internal cancer, there was a disproportionate representation of malignant neoplasms of the brain (especially sarcomas), and oral cavity (excluding tongue) compared to US whites under age 40 years. These internal neoplasms may be related to exposure to chemical environmental carcinogens that cause DNA damage which, like u.v.-induced damage, is poorly repaired by XP cells. These reports provide no evidence of an increase in XP of common lethal neoplasms such as lymphomas, or female genital tract or endocrine system cancers. These findings suggest that DNA repair plays a role in protection against u.v.-induced neoplasia and in protection against some internal neoplasms in the general population.

The DNA damage-binding protein XPC is a frequent target for inactivation in squamous cell carcinomas

XPC beyond nucleotide excision repair and skin cancers

Xeroderma Pigmentosum C: A Valuable Tool to Decipher the Signaling Pathways in Skin Cancers

XPC Polymorphism Increases Risk of Digestive System Cancers： Current Evidence from A Meta-Analysis

Xeroderma Pigmentosum Complementation Group C Protein (XPC) Expression in Basal Cell Carcinoma.

Nucleotide Excision Repair Gene Subunit Xpd is Highly Expressed in Cervical Squamous Cell Carcinoma

Xeroderma Pigmentosum Complementation Group C (XPC): Emerging Roles in Non-Dermatologic Malignancies

XPC initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms

Attenuated Expression of Xeroderma Pigmentosum Group C is Associated with Critical Events in Human Bladder Cancer Carcinogenesis and Progression

XPC Protects against Carcinogen-Induced Histologic Progression to Lung Squamous Cell Carcinoma by Reduced Basal Epithelial Cell Proliferation

DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum

491 Identification of Four Novel XPC Mutations in Two Xeroderma Pigmentosum Complementation Group C Patients and Functional Study of XPC Q320X Mutant

Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients

Identification of Four Novel XPC Mutations in Two Xeroderma Pigmentosum Complementation Group C Patients and Functional Study of XPC Q320X Mutant.

XPC deficiency increases risk of hematologic malignancies through mutator phenotype and characteristic mutational signature

Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated-A Systematic Review

Overexpression of Xeroderma Pigmentosum Group C Decreases the Chemotherapeutic Sensitivity of Colorectal Carcinoma Cells to Cisplatin

XPA-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of U.V.B

Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients

A novel missense variant and multiexon deletion causing a delayed presentation of xeroderma pigmentosum, group C

Development of effective skin cancer treatment and prevention in xeroderma pigmentosum